• Pubblicità

• Ultimi Articoli

  • Millionaire n°5 – Maggio 2012
  • Carlo Verdone: La casa sopra i portici/2 – Un giretto su una pantera della polizia
  • Carlo Verdone: La casa sopra i portici/1 – Per sempre
  • Vivere, lavorare, visitare luoghi in Svizzera
  • Dendreon Notable Links — For The Week Ending Friday, 18 May 2012.
  • Bologna, donna azzannata da cani Molossi per difendere il suo cagnolino
  • Un cane all’assalto di due ragazzini

• Tag Cloud

  Acquistare on line AGNC Antenna Telecom Vodafone Azioni Beppe Grillo Brasile Cancro alla prostata Cane ferisce adulto Cane ferisce minore Cani pericolosi CMS Dendreon Dividend Ideas Dividend Quick Picks & Lists DNDN editoria Fabio Fittizio farmacia farmaco FSC generico giornali Income Investing Strategy informazione Internet Bookshop Italia Investing for Income La casta bianca libertà di stampa Libri che sto scoprendo MPW Niobe NYB omeopatia OpenX Provenge referendum regime SBRA scoprire Seeking Alpha Stereotaxis Telefonate indesiderate Tiziano Terzani: Un altro giro di giostra vino WordPress

• Pubblicità

• Blogroll

  • Artifex -Tutto quanto fa ex libris Notizie, interviste, concorsi, artisti, premi, profili, informazioni sugli ex libris
  • Dog Bite Law Sito statunitense dedicato alle vittime di attacchi di cani

• Economia

  • Tim Harford Il sito di Tim Harford

• Finanza

  • Mercato Libero Una chiave diversa rispetto alla lettura dell’economia dei media italiani
  • Thoughts from the Frontline Il sito che diffonde la newsletter di John Mauldin

• Politica

  • Il blog di Beppe Grillo Gli italiani sentono il rumore della cascata, sanno di essere su una barca piena di buchi, ma finché non precipiteranno nelle rapide, in molti rimarranno a guardare.

di Giancarlo Nicoli

My latest Seeking Alpha:

http://seekingalpha.com/article/388281-setting-up-a-laid-back-high-yield-portfolio

Tags:
AGNC, FSC, SBRA, MPW, NYB, Investing for Income, Income Investing Strategy, Dividend Ideas, Dividend Quick Picks & Lists.

Tags:

di Giancarlo Nicoli

My latest Seeking Alpha:

http://seekingalpha.com/article/350251-3-sustainable-picks-for-laid-back-dividend-investing-and-1-to-worry-about

Companies covered:

• Sabra Health Care REIT, Inc. (SBRA)
• Medical Properties Trust, Inc. (MPW)
• New York Community Bancorp Inc. (NYB)
• Cellcom Israel, Ltd. Ordinary S (CEL)

Tags:

di Giancarlo Nicoli

Dendreon (DNDN)’s Provenge works. This article is a little guide to restore accurate info regarding Provenge cost and survival advantage.

Dana Blankenhorn says:

While it has survived Phase III trials, fact is it’s only shown to extend life by about four months – and it costs $93,000.

Addressing survival: The above mistake is still common. Those “about four months” are now something mythical, widely talked about. It mystifies me that there’s still someone using them without context. The 4.1 month median survival benefit is, er, median. It is not an average. Median survivalmeans that half of all patients in the Phase III trials experienced a life-extending benefit of less than 4.1 months, while half of the men had their lives extended by a longer period of time, some up to 7 to 8 years.

What’s more, the Phase III trials design accounted for some underestimating of Provenge survival benefit. According to exploratory data analysis, true median overall survival benefit of Provenge in the Phase 3 IMPACT trial was estimated to be 7.8 months (Source: Dendreon).

Addressing cost: The full Provenge treatment costs $93,000. Another Prostate Cancer treatment is Zytiga (which must be taken with prednisone and which has a median treatment length of 8 months) costs $72,000 per year. Avastin can cost up to $100,000 per year.
Provenge has a very favorable safety profile. The most common side effects reported with Provenge treatment are: Chills, fatigue, fever, back pain, nausea, joint ache, headache (source: Provenge.com). They usually last a couple of days at most and do not require hospitalization – as opposed to other treatments that are toxic and that do require costly hospitalization. This cost is not included in the cost the treatment, and can run for several tens of thousands of dollars per patient.

Tags:

di Giancarlo Nicoli

A couple of rumors yesterday regarding Dendreon Corporation (DNDN).

Shares surged, on more than tripled average turnover, almost 17% reportedly after U.S. health regulators published a critical review of rival Amgen Inc.’s (AMGN) drug for prostate cancer. Where’s the connection between FDA review of Amgen’s drug and Dendreon is puzzling me.

Anyway.

Rumor #1: January turnover much bigger than expected.

Rumor #2: Amgen is going to buy DNDN out. With an offer in the $21 range.

These are rumors, not news, there are no PRs and no confirmations anywhere.
Take these rumors with plenty of salt.

Tags:

di Giancarlo Nicoli

My latest Seeking Alpha:

Sustainable Picks For Laid-Back Dividend Investing

Tags:

di Giancarlo Nicoli

Giancarlo Nicoli adheres to

Seeking Alpha’s Gold Standard Compliance

 1. Author qualification
* Authors attest that they have never been prosecuted on any securities-related issue, that they have never been barred from the securities industry, or convicted of a felony. (If you cannot agree to point 1 above but would still like to become a Seeking Alpha contributor, please contact us at contributors@seekingalpha.com).

 2. Disclosure of positions and intention to purchase securities
* Authors agree to disclose the existence at the time of writing of a long or short position (including stocks, options or other instruments) in any stock mentioned in an article. The suggested form of disclosure is to add the disclosure in the following format to the bottom of articles: “Disclosure: Long GOOG at time of writing”. If the author has no position in stocks mentioned, that should be indicated in the following format: “Disclosure: No position in stocks mentioned’
* Authors may not write about a stock with the intention to boost or reduce the stock’s price and sell (or buy) the stock into the resulting strength or weakness.
* If the author intends at the time of writing to sell or buy a stock within three days of publication of an article that discusses that stock, the author must disclose this.

 3. Disclosure of business relationships and conflicts of interest; no Investor Relations professionals
* Authors agree to disclose in the footer of posts any and all personal, material relationships with companies whose stocks they write about, or personal, material relationships with parties that stand to gain from the viewpoint they are outlining. Examples: authors must disclose if they are employed by a company whose stock they are writing about; perform consulting for a company they write about; receive paid advertising revenue or any other form of sponsorship fee from a company they write about. This applies to narrow asset classes as well. For example, if an author is paid to promote a gold dealer, that must be disclosed in any article about gold.
* Authors may not work in the field of investor relations. We will not accept articles from authors who work in the field of investor relations, even if the article focuses on companies with which the author has no business relationship.

4. Non-Infringement of Copyright
* Authors attest that any articles submitted for publication to Seeking Alpha do not infringe upon the rights of any other party. If other sources are quoted, the source must be clearly cited (and linked to when possible) and the quote must be within the parameters of Fair Use.

 5. Commitment to Accuracy
* Authors certify that all facts in articles submitted to Seeking Alpha are accurate to the best of his/her knowledge.

6. Author’s websites, promotion and other material
* Authors’ web sites, which Seeking Alpha will be asked to link to, may not contain any illegal material, racism or pornography.
* Authors must substantiate publicly any claims regarding their investment track records that are stated on their web sites, if such a claims are made.
* Authors may not make any guarantees or explicit predictions regarding the market performance that subscribers to their paid newsletters or other services can expect.
* Authors’ web sites must not contain sensationalist language about stocks, e.g. “rocket” or “set to soar.”

 7. Anonymity and accountability
* Authors agree to provide their real names, phone number and an active email to Seeking Alpha, even if they intend their articles to be published anonymously under a pseudonym.

Tags:

di Giancarlo Nicoli

My latest Seeking Alpha:

http://seekingalpha.com/article/332852-dendreon-corp-s-latest-developments-what-they-mean

Tags:

← Previous Page — Next Page →

• Search for:

• Seeking Alpha Gold Certification

  

  
  
  
  
  
  
  
  

• Categorie

  • A Como e dintorni
  • A Milano
  • Alimentazione
  • Appiano Gentile
  • Attacchi di cani a persone
  • Beppe Grillo sì e no
  • Celiachia
  • Cinema
  • Comprare sembra facile
  • Dendreon
  • Girare in giro, mangiare, bere, divertirsi
  • Il mestiere di farmacista
  • Il Rosso e il Verde
  • Investimenti
  • Letterature
  • Liberista
  • Libertà
  • Libri che sto scoprendo
  • Marketing
  • Mondo cane
  • Mondo Internet
  • Persone
  • Politica
  • Start Up e Venture Capital
  • Stereotaxis
  • Stili di vita
  • Te lo do io il Brasile
  • Tutto il resto
  • TV

• Pubblicità

• Meta

  • Register
  • Log in
  • Entries RSS
  • Comments RSS
  • WordPress.org

• Pubblicità: Amazon.it

  
  
  
  
  
  

• Creative Common License

  
  Questo/a opera è pubblicato sotto una Licenza Creative Commons